554 related articles for article (PubMed ID: 31419295)
1. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
Checkmahomed L; M'hamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
J Infect Dis; 2020 Jan; 221(1):63-70. PubMed ID: 31419295
[TBL] [Abstract][Full Text] [Related]
2. Replication and transmission of an influenza A(H3N2) virus harboring the polymerase acidic I38T substitution, in guinea pigs.
Mhamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
J Gen Virol; 2021 Oct; 102(10):. PubMed ID: 34661516
[TBL] [Abstract][Full Text] [Related]
3. Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice.
Abed Y; Fage C; Checkmahomed L; Venable MC; Boivin G
Antiviral Res; 2020 Jul; 179():104807. PubMed ID: 32343991
[TBL] [Abstract][Full Text] [Related]
4. Replicative Fitness of Seasonal Influenza A Viruses With Decreased Susceptibility to Baloxavir.
Chesnokov A; Patel MC; Mishin VP; De La Cruz JA; Lollis L; Nguyen HT; Dugan V; Wentworth DE; Gubareva LV
J Infect Dis; 2020 Jan; 221(3):367-371. PubMed ID: 31541547
[TBL] [Abstract][Full Text] [Related]
5. Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility.
Jones JC; Pascua PNQ; Fabrizio TP; Marathe BM; Seiler P; Barman S; Webby RJ; Webster RG; Govorkova EA
Proc Natl Acad Sci U S A; 2020 Apr; 117(15):8593-8601. PubMed ID: 32217734
[TBL] [Abstract][Full Text] [Related]
6. Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model.
Koszalka P; George A; Dhanasekaran V; Hurt AC; Subbarao K
mBio; 2022 Aug; 13(4):e0105622. PubMed ID: 35938724
[TBL] [Abstract][Full Text] [Related]
7. Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil.
Nakauchi M; Takashita E; Fujisaki S; Shirakura M; Ogawa R; Morita H; Miura H; Saito S; Watanabe S; Odagiri T; Kageyama T
Influenza Other Respir Viruses; 2020 Jul; 14(4):436-443. PubMed ID: 32064779
[TBL] [Abstract][Full Text] [Related]
8. Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility.
Osada H; Chon I; Phyu WW; Wagatsuma K; Nagata N; Kawashima T; Sato I; Saito T; Kodo N; Masaki H; Asoh N; Tsuchihashi Y; Shirahige Y; Ono Y; Shimada Y; Hamabata H; Saito K; Saito R
Antiviral Res; 2021 Apr; 188():105036. PubMed ID: 33577807
[TBL] [Abstract][Full Text] [Related]
9. Influenza A virus polymerase acidic protein E23G/K substitutions weaken key baloxavir drug-binding contacts with minimal impact on replication and transmission.
Jones JC; Zagribelnyy B; Pascua PNQ; Bezrukov DS; Barman S; Okda F; Webby RJ; Ivanenkov YA; Govorkova EA
PLoS Pathog; 2022 Jul; 18(7):e1010698. PubMed ID: 35830486
[TBL] [Abstract][Full Text] [Related]
10. Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019.
Takashita E; Kawakami C; Ogawa R; Morita H; Fujisaki S; Shirakura M; Miura H; Nakamura K; Kishida N; Kuwahara T; Ota A; Togashi H; Saito A; Mitamura K; Abe T; Ichikawa M; Yamazaki M; Watanabe S; Odagiri T
Euro Surveill; 2019 Mar; 24(12):. PubMed ID: 30914078
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses.
Kuroda T; Fukao K; Yoshida S; Oka R; Baba K; Ando Y; Taniguchi K; Noshi T; Shishido T
Viruses; 2023 May; 15(5):. PubMed ID: 37243240
[TBL] [Abstract][Full Text] [Related]
12. Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019.
Takashita E; Ichikawa M; Morita H; Ogawa R; Fujisaki S; Shirakura M; Miura H; Nakamura K; Kishida N; Kuwahara T; Sugawara H; Sato A; Akimoto M; Mitamura K; Abe T; Yamazaki M; Watanabe S; Hasegawa H; Odagiri T
Emerg Infect Dis; 2019 Nov; 25(11):2108-2111. PubMed ID: 31436527
[TBL] [Abstract][Full Text] [Related]
13. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018.
Takashita E; Kawakami C; Morita H; Ogawa R; Fujisaki S; Shirakura M; Miura H; Nakamura K; Kishida N; Kuwahara T; Mitamura K; Abe T; Ichikawa M; Yamazaki M; Watanabe S; Odagiri T;
Euro Surveill; 2019 Jan; 24(3):. PubMed ID: 30670142
[TBL] [Abstract][Full Text] [Related]
14. Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets.
Imai M; Yamashita M; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Kiso M; Murakami J; Yasuhara A; Takada K; Ito M; Nakajima N; Takahashi K; Lopes TJS; Dutta J; Khan Z; Kriti D; van Bakel H; Tokita A; Hagiwara H; Izumida N; Kuroki H; Nishino T; Wada N; Koga M; Adachi E; Jubishi D; Hasegawa H; Kawaoka Y
Nat Microbiol; 2020 Jan; 5(1):27-33. PubMed ID: 31768027
[TBL] [Abstract][Full Text] [Related]
15. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.
Gubareva LV; Mishin VP; Patel MC; Chesnokov A; Nguyen HT; De La Cruz J; Spencer S; Campbell AP; Sinner M; Reid H; Garten R; Katz JM; Fry AM; Barnes J; Wentworth DE
Euro Surveill; 2019 Jan; 24(3):. PubMed ID: 30670144
[TBL] [Abstract][Full Text] [Related]
16. Mutated influenza A virus exhibiting reduced susceptibility to baloxavir marboxil from an experimentally infected horse.
Nemoto M; Tamura N; Bannai H; Tsujimura K; Kokado H; Ohta M; Yamanaka T
J Gen Virol; 2019 Nov; 100(11):1471-1477. PubMed ID: 31526451
[TBL] [Abstract][Full Text] [Related]
17. Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment.
Takashita E; Abe T; Morita H; Nagata S; Fujisaki S; Miura H; Shirakura M; Kishida N; Nakamura K; Kuwahara T; Mitamura K; Ichikawa M; Yamazaki M; Watanabe S; Hasegawa H;
Antiviral Res; 2020 Aug; 180():104828. PubMed ID: 32574689
[TBL] [Abstract][Full Text] [Related]
18. Influenza A virus polymerase acidic protein E23R substitution is a marker of reduced susceptibility to baloxavir.
Jones JC; Rovito SW; Penaflor MK; Webby RJ; Govorkova EA
Antiviral Res; 2022 Aug; 204():105369. PubMed ID: 35738347
[TBL] [Abstract][Full Text] [Related]
19. The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir.
Taniguchi K; Noshi T; Omoto S; Sato A; Shishido T; Matsuno K; Okamatsu M; Krauss S; Webby RJ; Sakoda Y; Kida H
Arch Virol; 2024 Jan; 169(2):29. PubMed ID: 38216710
[TBL] [Abstract][Full Text] [Related]
20. Impact of Baloxavir Resistance-Associated Substitutions on Influenza Virus Growth and Drug Susceptibility.
Hickerson BT; Petrovskaya SN; Dickensheets H; Donnelly RP; Ince WL; Ilyushina NA
J Virol; 2023 Jul; 97(7):e0015423. PubMed ID: 37404185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
